
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
However, some challenges still limit its implementation in clinical practice
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients
Promising results support the further development of new small-molecule PD-L1 inhibitors with favourable benefit–risk profiles and improved ease of use compared with antibodies
Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab
Novel treatment approaches show encouraging early results in solid tumours, but ways to boost precision immunotherapy are needed
Several studies report on promising data with immunomodulation and alternative approaches
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.